Leveraging Genetically Guided Antibody Strategies to Repair Barrier Dysfunction and Immune Dysregulation in Atopic Dermatitis
Time: 4:00 pm
day: Day One PM
Details:
- Dual inhibition of kallikrein‑5 and ‑7 offers a protease‑based mechanism that intersects barrier dysfunction, inflammation, and itch in AD
- Unlike standard Th2‑targeted biologics, targeting KLK5/7 represents an orthogonal pathway informed by Netherton syndrome genetics and human expression datasets ex vivo human explant data show rapid improvements in epidermal integrity, reduced keratinocyte proliferation, and restoration of barrier proteins such as desmoglein‑1
- A next‑generation bispecific antibody combining KLK5/7 inhibition with IL‑13 blockade is being advanced to enhance efficacy across barrier and inflammation axes
